Skip to main content
. Author manuscript; available in PMC: 2011 Oct 30.
Published in final edited form as: Am J Hypertens. 2011 Jun 30;24(10):1149–1155. doi: 10.1038/ajh.2011.114

Figure 3.

Figure 3

Effect of Ang II on insulin-induced protein synthesis and cell hypertrophy. (a) VSMCs were pretreated with Ang II (100 nmol/l) for 18 h and then exposed to with the indicated concentrations of insulin for 24 h. (b) Cells were pretreated with MAP kinase inhibitors (SB203580; 10 μmol/l, SP600125; 20 μmol/l, PD98059; 10 μmol/l), wortmannin (100 nmol/l) or an antioxidant (ebselen; 40 μmol/l) before insulin (10 nmol/l) incubation (30 min). The ARB (RNH-6270; 100 nmol/l) pretreated before Ang II incubation (30 min). Protein synthesis was measured by [3H]-leucine incorporation. (c) Cell volume was measured by a Coulter Cell Multisizer. Data represent mean ± s.e. (n = 6), expressed as fold change compared with unstimulated cells. Two-way ANOVA showed that the dose-dependent increase of [3H]-leucine incorporation was significantly higher in Ang II-pretreated VSMCs than in control VSMCs. *P < 0.05 vs. control VSMCs. **P < 0.05 vs. Ang II-pretreated VSMCs without insulin. #P < 0.05 vs. insulin treatment in Ang II-pretreated VSMCs. Ang II, angiotensin II; ARB, Ang II type 1 receptor blockers; MAP, mitogen-activated protein; VSMCs, vascular smooth muscle cells.